---
category: news
title: "Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC"
excerpt: "OnKai's AI models redefine the methodologies and economics of clinical trials TEL AVIV, Israel, July 10, 2023 /PRNewswire/ -- Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) (\"Galmed\" or the \"Company\"), a"
publishedDateTime: 2023-07-10T12:00:00Z
originalUrl: "https://www.benzinga.com/pressreleases/23/07/n33164058/galmed-to-employ-onkais-disruptive-artificial-intelligence-ai-in-its-planned-phase-2a-clinical-tri"
webUrl: "https://www.benzinga.com/pressreleases/23/07/n33164058/galmed-to-employ-onkais-disruptive-artificial-intelligence-ai-in-its-planned-phase-2a-clinical-tri"
ampWebUrl: "https://www.benzinga.com/amp/content/33164058"
cdnAmpWebUrl: "https://www-benzinga-com.cdn.ampproject.org/c/s/www.benzinga.com/amp/content/33164058"
type: article

provider:
  name: Benzinga.com
  domain: benzinga.com

topics:
  - AI in Healthcare
  - AI

images:
  - url: "https://www.benzinga.com/next-assets/images/schema-image-default.png"
    width: 1043
    height: 1043
    isCached: true

secured: "HR7qKiaSD6pXgVyS53wy0ZXCOikR7A7o1U+GKooYxJ8MlShKr2todVhd3bZ843Yjz0cx8mjonzWambgFfjuXaggDRIfUZmckLxNFME1HRhrU+ldX5OG25sfSD4sIPZpHcrjoDHtKX/ln2ZIMgEUIsy4Xx56rV3XkdVD2uwEwrfVmo+6giIJhm8J/1VHPZH4Kk9AgBm6aT93RmYQbNIjnSYywNlhvXM0xUG+0JCmEMCzLm0b2i6yJaUR4xu50hOMjqKac0sHz4VzVFslNUXKZyr1y0m8VfUw1DaOdQ9mpO9IiZDeYzkd+SxraFad7BSx8uMADYUBHDjpi1B9Qw+/tEH0Wyf9ELdGgBiMUdy0Wvcc=;ud49jOLQ7qE9lzxy9FVbBw=="
---

